Cd19tm1(cre)Cgn/Cd19+
Map3k7tm1Aki/Map3k7tm1.1Aki
involves: 129P2/OlaHsd * C57BL/6
|
abnormal B cell physiology |
J:112597
|
|
decreased B cell proliferation |
J:112597
|
|
decreased B-1 B cell number |
J:112597
|
|
decreased IgG1 level |
J:112597
|
|
decreased IgG3 level |
J:112597
|
|
decreased IgG level |
J:112597
|
|
decreased immunoglobulin level |
J:112597
|
Map3k7Gt(XB444)Byg/Map3k7Gt(XB444)Byg
involves: 129P2/OlaHsd * C57BL/6
|
embryonic lethality during organogenesis, complete penetrance |
J:102721
|
|
open neural tube |
J:102721
|
|
wavy neural tube |
J:102721
|
Map3k7Gt(XB444)Byg/Map3k7Gt(XB444)Byg
involves: 129P2/OlaHsd * C57BL/6J
|
abnormal blood vessel morphology |
J:107401
|
|
abnormal dorsal aorta morphology |
J:107401
|
|
abnormal heart morphology |
J:107401
|
|
abnormal myocardial trabeculae morphology |
J:107401
|
|
abnormal pharyngeal arch artery morphology |
J:107401
|
|
abnormal vascular development |
J:107401
|
|
abnormal vascular regression |
J:107401
|
|
abnormal vascular smooth muscle morphology |
J:107401
|
|
abnormal vitelline vascular remodeling |
J:107401
|
|
abnormal vitelline vasculature morphology |
J:107401
|
|
decreased embryo size |
J:107401
|
|
edema |
J:107401
|
|
embryo tissue necrosis |
J:107401
|
|
embryonic lethality during organogenesis, complete penetrance |
J:107401
|
|
hemorrhage |
J:107401
|
|
microcephaly |
J:107401
|
|
pericardial edema |
J:107401
|
|
short tail |
J:107401
|
|
small heart |
J:107401
|
|
thin myocardium compact layer |
J:107401
|
Map3k7tm1.1Aki/Map3k7tm1.1Aki
involves: 129P2/OlaHsd * C57BL/6
|
absent fibroblast proliferation |
J:112597
|
|
embryonic lethality during organogenesis, complete penetrance |
J:112597
|
Map3k7tm1.1Gkl/Map3k7tm1.1Gkl
Lyz2tm1(cre)Ifo/Lyz2+
involves: 129P2/OlaHsd * C57BL/6
|
decreased circulating interleukin-10 level |
J:211916
|
|
decreased interleukin-10 secretion |
J:211916
|
|
increased circulating interleukin-1 beta level |
J:211916
|
|
increased circulating tumor necrosis factor level |
J:211916
|
|
increased inflammatory response |
J:211916
|
|
increased interleukin-1 beta secretion |
J:211916
|
|
increased interleukin-6 secretion |
J:211916
|
|
increased interleukin-10 secretion |
J:211916
|
|
increased susceptibility to endotoxin shock |
J:211916
|
|
increased susceptibility to induced morbidity/mortality |
J:211916
|
|
increased tumor necrosis factor secretion |
J:211916
|
Map3k7tm1.1Mds/Map3k7tm1.1Mds
Not Specified
|
abnormal blood vessel morphology |
J:117108
|
|
abnormal vitelline vasculature morphology |
J:117108
|
|
embryonic lethality during organogenesis, complete penetrance |
J:117108
|
Map3k7tm1.2Gkl/Map3k7tm1.2Gkl
involves: C57BL/6 * FVB/N
|
prenatal lethality, complete penetrance |
J:211916
|
Map3k7tm1Aki/Map3k7tm1Aki
Speer6-ps1Tg(Alb-cre)21Mgn/Speer6-ps1+
involves: 129P2/OlaHsd * C57BL/6 * DBA/2
|
abnormal bile duct morphology |
J:160521
|
|
abnormal hepatocyte morphology |
J:160521
|
|
focal hepatic necrosis |
J:160521
|
|
increased circulating bilirubin level |
J:160521
|
|
increased hepatocyte proliferation |
J:160521
|
Map3k7tm1Aki/Map3k7tm1Aki
Tg(Alb1-cre)7Gsc/0
involves: 129P2/OlaHsd * FVB/N
|
abnormal bile duct morphology |
J:160521
|
|
abnormal hepatocyte morphology |
J:160521
|
|
abnormal liver morphology |
J:160521
|
|
bile duct proliferation |
J:160521
|
|
focal hepatic necrosis |
J:160521
|
|
increased circulating alanine transaminase level |
J:160521
|
|
increased circulating alkaline phosphatase level |
J:160521
|
|
increased circulating aspartate transaminase level |
J:160521
|
|
increased circulating bilirubin level |
J:160521
|
|
increased circulating glutamate dehydrogenase level |
J:160521
|
|
increased hepatocellular carcinoma incidence |
J:160521
|
|
increased hepatocyte apoptosis |
J:160521
|
|
increased hepatocyte proliferation |
J:160521
|
|
intrahepatic cholestasis |
J:160521
|
|
liver fibrosis |
J:160521
|
|
liver inflammation |
J:160521
|
|
premature death |
J:160521
|
Map3k7tm1Aki/Map3k7tm1Aki
Tg(Lck-cre)1Jtak/0
involves: 129P2/OlaHsd
|
abnormal colon morphology |
J:112837
|
|
abnormal intestinal goblet cell morphology |
J:112837
|
|
abnormal intestine morphology |
J:112837
|
|
abnormal spleen morphology |
J:112837
|
|
abnormal T cell activation |
J:112837
|
|
absent regulatory T cells |
J:112837
|
|
chronic diarrhea |
J:112837
|
|
colitis |
J:112837
|
|
decreased CD4-positive, alpha-beta T cell number |
J:112837
|
|
decreased CD8-positive, alpha-beta T cell number |
J:112837
|
|
decreased single-positive T cell number |
J:112837
|
|
decreased T cell number |
J:112837
|
|
decreased T cell proliferation |
J:112837
|
|
enlarged lymph nodes |
J:112837
|
|
enlarged spleen |
J:112837
|
|
increased memory T cell number |
J:112837
|
|
intestinal ulcer |
J:112837
|
|
rectal prolapse |
J:112837
|
|
spleen hyperplasia |
J:112837
|
|
weight loss |
J:112837
|
Map3k7tm1Aki/Map3k7tm1Aki
Tg(Lck-cre)1Jtak/0
involves: 129P2/OlaHsd * C57BL/6
|
abnormal alpha-beta intraepithelial T cell morphology |
J:238318
|
|
abnormal CD4-positive, alpha-beta T cell physiology |
J:238318
|
|
abnormal cytokine level |
J:238318
|
|
abnormal intestinal epithelium physiology |
J:238318
|
|
abnormal intraepithelial T cell number |
J:238318
|
|
abnormal liver morphology |
J:238318
|
|
abnormal regulatory T cell number |
J:238318
|
|
abnormal regulatory T cell physiology |
J:238318
|
|
abnormal T cell morphology |
J:238318
|
|
colitis |
J:238318
|
|
decreased CD4-positive, CD25-positive, alpha-beta regulatory T cell number |
J:238318
|
|
decreased NK T cell number |
J:238318
|
|
increased CD4-positive, alpha-beta T cell number |
J:238318
|
|
increased gamma-delta intraepithelial T cell number |
J:238318
|
|
increased interferon-gamma secretion |
J:238318
|
|
increased interleukin-17 secretion |
J:238318
|
Map3k7tm1Aki/Map3k7tm1Aki
Tg(Slco1c1-icre/ERT2)1Mrks/0
involves: 129P2/OlaHsd * C57BL/6 * DBA/2
|
normal
behavior/neurological phenotype |
J:179050
|
|
decreased locomotor activity |
J:179050
|
|
normal
growth/size/body region phenotype |
J:179050
|
|
normal
homeostasis/metabolism phenotype |
J:179050
|
|
impaired febrile response |
J:179050
|
|
lethargy |
J:179050
|
Map3k7tm1Aki/Map3k7tm1Aki
Tg(Slco1c1-icre/ERT2)1Mrks/0
involves: 129P2/OlaHsd * C57BL/6 * SJL
|
normal
behavior/neurological phenotype |
J:179050
|
|
normal
homeostasis/metabolism phenotype |
J:179050
|
Map3k7tm1Aki/Map3k7tm1Aki
Tg(Tek-cre)12Flv/0
involves: 129P2/OlaHsd * C3H * C57BL/6
|
abnormal vascular development |
J:191285
|
|
abnormal vitelline vasculature morphology |
J:191285
|
|
normal
cardiovascular system phenotype |
J:191285
|
|
decreased angiogenesis |
J:191285
|
|
embryonic lethality during organogenesis, complete penetrance |
J:191285
|
|
increased apoptosis |
J:191285
|
Map3k7tm1b(EUCOMM)Wtsi/Map3k7+
C57BL/6N-Map3k7tm1b(EUCOMM)Wtsi/H
|
abnormal lens morphology |
J:211773
|
|
increased circulating alkaline phosphatase level |
J:211773
|
Map3k7tm1b(EUCOMM)Wtsi/Map3k7tm1b(EUCOMM)Wtsi
C57BL/6N-Map3k7tm1b(EUCOMM)Wtsi/H
|
embryonic lethality prior to tooth bud stage |
J:211773
|
|
preweaning lethality, complete penetrance |
J:211773
|
Map3k7tm1Mds/Map3k7tm1Mds
Tg(Myh6-cre)2182Mds/0
involves: FVB/N
|
embryonic lethality during organogenesis, complete penetrance |
J:117108
|
Map3k7tm1Mis/Map3k7tm1Mis
H2az2Tg(Wnt1-cre)11Rth/H2az2+
involves: C57BL/6J * CBA/J
|
abnormal craniofacial morphology |
J:198588
|
|
abnormal secondary palate development |
J:198588
|
|
cleft secondary palate |
J:198588
|
|
decreased cranium height |
J:198588
|
|
failure of palatal shelf elevation |
J:198588
|
|
neonatal lethality, complete penetrance |
J:198588
|
|
palatal shelf hypoplasia |
J:198588
|
|
short mandible |
J:198588
|
|
short maxilla |
J:198588
|
Map3k7tm1Zjc/Map3k7tm1Zjc
Tg(Lck-cre)548Jxm/0
involves: 129S7/SvEvBrd * C57BL/6 * CBA
|
decreased CD4-positive, alpha-beta T cell number |
J:111794
|
|
decreased CD8-positive, alpha-beta T cell number |
J:111794
|
|
decreased T cell number |
J:111794
|
|
increased thymocyte apoptosis |
J:111794
|
Tg(CAG-Map3k7*K63W)1232Mds/0
Tg(Myh6-cre)2182Mds/0
involves: FVB/N
|
abnormal atrial thrombosis |
J:117108
|
|
abnormal cardiovascular system physiology |
J:117108
|
|
abnormal heart morphology |
J:117108
|
|
abnormal myocardial fiber morphology |
J:117108
|
|
abnormal QRS complex |
J:117108
|
|
abnormal ventricle papillary muscle morphology |
J:117108
|
|
cardiac hypertrophy |
J:117108
|
|
cardiomyopathy |
J:117108
|
|
decreased locomotor activity |
J:117108
|
|
dilated heart ventricle |
J:117108
|
|
increased cardiac muscle glycogen level |
J:117108
|
|
periorbital edema |
J:117108
|
|
postnatal growth retardation |
J:117108
|
|
postnatal lethality, complete penetrance |
J:117108
|
|
prolonged QRS complex duration |
J:117108
|
|
shortened PR interval |
J:117108
|
|
thin ventricular wall |
J:117108
|
Excel File
Analysis Tools